Ruxolitinib in clinical practice for therapy of myelofibrosis: Single USA center experience following Food and Drug Administration approval

Leukemia and Lymphoma

Volumn 55, Issue 1, 2014, Pages 195-197

  Geyer, Holly ^a   Cannon, Keith ^a   Knight, Emily ^a   Fauble, Veena ^a   Camoriano, John ^a   Emanuel, Robyn ^a   Tibes, Raoul ^a   Mesa, Ruben ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DANAZOL; HEMOGLOBIN; RUXOLITINIB;

ABDOMINAL PAIN; AGED; ANEMIA; AUTONOMIC NEUROPATHY; BODY WEIGHT DISORDER; CANCER CHEMOTHERAPY; CANCER FATIGUE; CLINICAL ARTICLE; CLINICAL PRACTICE; DISEASE EXACERBATION; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH DISPARITY; HEMOGLOBIN DETERMINATION; HUMAN; HYPERKALEMIA; LETTER; MALE; MYELOFIBROSIS; NIGHT SWEAT; PRIORITY JOURNAL; PRURITUS; SPLENOMEGALY; STEM CELL TRANSPLANTATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; UNITED STATES; VERY ELDERLY;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; HUMANS; JANUS KINASES; PRIMARY MYELOFIBROSIS; PYRAZOLES; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84887954865     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.789507     Document Type: Letter

References (12)

1. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): An international internet-based survey of 1179 MPD patients. Cancer 2007; 109: 68-76.
2. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients. Blood 2011; 118: 401-408.
3. Barosi G, Mesa RA, Th iele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofi brosis: A consensus statement from the International Working Group for Myelofi brosis Research and Treatment. Leukemia 2008; 22: 437-438.
4. Hoffman R, Rondelli D. B iology and treatment of primary myelofi brosis. Hematology Am Soc Hematol Educ Program 2007: 346-354.
5. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofi brosis based on a study of the International Working Group for Myelofi brosis Research and Treatment. Blood 2009; 113: 2895-2901.
6. Mesa RA, L i CY, Ketterling RP, et al. Leukemic transformation in myelofi brosis with myeloid metaplasia: A single-institution experience with 91 cases. Blood 2005; 105: 973-977.
7. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
8. Trelinski J, Wierzbowska A, Krawczynska A, et al. Circulating endothelial cells in essential thrombocythemia and polycythemia vera: Correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers. Int J Hematol 2010; 91: 792-798.
9. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
10. Harrison C, Kiladjian JJ, A l-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofi brosis. N Engl J Med 2012; 366: 787-798.
11. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebocontrolled trial of ruxolitinib for myelofi brosis. N Engl J Med 2012; 366: 799-807.
12. Passamonti F, Cervantes F, Vannucchi A M,et al. A dynamic prognostic model to predict survival in primary myelofi brosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703-1708.